We bridge the space between early-stage discovery and clinical translation — bringing the depth of physician-scientist training to every strategic conversation, with patients at the center of every decision.
Aria Translational Group was founded on a conviction held by those who have lived in both worlds: the most transformative medicines begin with deep mechanistic insight, and the path from discovery to patient requires fluency in both the language of the laboratory and the language of the clinic.
"Innovation only becomes impact when it reaches the patient who needs it."
As physician-scientists with active research and clinical practices in oncology, we occupy a rare and privileged intersection. We help early-stage academic discoveries find their rightful clinical context — and help therapeutic programs navigate the complex terrain between proof-of-concept and patient care.
Whether you are a basic scientist with a compelling target, a biotech team seeking translational strategy, or an institution looking to align research programs with therapeutic opportunity, ATG brings the perspective and partnership to move the work forward.
Active clinical practice providing firsthand insight into patient need, treatment landscape, and therapeutic gaps that matter at the bedside.
Research expertise in tumor suppressors, cell-state and cell-fate dynamics, and mechanism-driven drug development.
Bridging early discovery to clinical placement — from target identification and validation through indication selection and development planning.
Deep academic roots paired with pragmatic industry perspective, enabling productive dialogue across both ecosystems.
Every breakthrough begins with a question asked more carefully than the last. We engage with biological problems at the level of mechanism — committed to understanding before proposing, and to pursuing the questions others have not yet thought to ask.
Patients are never abstractions. They are the reason this work matters. Every scientific and strategic decision we make is filtered through the lens of clinical reality, patient experience, and the urgency of unmet need.
The gap between discovery and medicine is bridged by people, not programs. We invest in genuine scientific partnership — building trust across disciplines, institutions, and career stages to move the science forward together.
We evaluate early-stage discoveries for therapeutic potential — assessing target biology, mechanistic plausibility, novelty, and the strength of the foundational evidence. We help identify what is compelling and what needs further development before moving forward.
From target to therapeutic hypothesis to development plan — we map the translational path, identifying critical experiments, biomarker strategies, indication selection, and patient population considerations that define the clinical arc.
Knowing where a therapy belongs in the clinic is as important as the science itself. We leverage deep oncology expertise to align emerging therapies with the right patient populations, disease settings, and competitive landscape considerations.
We serve as long-term scientific advisors for academic labs, biotech startups, and venture-backed programs — providing ongoing mechanistic and clinical perspective to refine research directions, grant narratives, and investor storytelling.
We engage deeply with the foundational biology — the mechanism, the evidence, the unknowns — before offering any strategic perspective.
We apply clinical experience to evaluate where the science could matter most — which patients, which disease contexts, which unmet needs are most compelling.
We develop a clear translational narrative — connecting molecular mechanism to clinical hypothesis and outlining the milestones that validate the path.
We stay engaged through execution — refining strategy as data emerges, facilitating connections, and championing the science with the patient in view.
Whether you have a compelling discovery, a strategic question, or simply want to explore how ATG might serve as a scientific partner — we welcome the conversation. Every meaningful therapy starts somewhere.
"The ATG codon is where every protein begins. Let us help you find your beginning."